{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T11:57:45Z","timestamp":1792929465291,"version":"4.5.0"},"reference-count":99,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences and Health Services","doi-asserted-by":"publisher","award":["1402\\u20134\\u2013107\\u201369972"],"award-info":[{"award-number":["1402\\u20134\\u2013107\\u201369972"]}],"id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Translational Medicine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.retram.2025.103563","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T08:00:34Z","timestamp":1765958434000},"page":"103563","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Lipid nanoparticle mediated delivery of Anti-CD19 CAR mRNA to umbilical cord blood NK cells for targeting CD19\u207a primary B-ALL cells"],"prefix":"10.1016","volume":"74","author":[{"given":"Hossein","family":"Salehi-Shadkami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mosslim","family":"Sedghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shima","family":"Tavoosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoumeh","family":"Alimohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Alimohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Barkhordar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmadreza","family":"Mofayezi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Sadra","family":"Modaresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Vaezi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somaye","family":"Dehghanizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Ahmadvand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahid","family":"Khoddami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.retram.2025.103563_bib0001","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/j.seminhematol.2023.11.004","article-title":"Epidemiology and etiology of diffuse large B-cell lymphoma","volume":"60","author":"Wang","year":"2023","journal-title":"Semin Hematol"},{"issue":"6","key":"10.1016\/j.retram.2025.103563_bib0002","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a034819","article-title":"Epidemiology and etiology of leukemia and lymphoma","volume":"10","author":"Bispo","year":"2020","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"10.1016\/j.retram.2025.103563_bib0003","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1080\/10428194.2021.1975188","article-title":"Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020\u20132025","volume":"63","author":"Kanas","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.retram.2025.103563_bib0004","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/annonc\/mdl443","article-title":"Epidemiology of hematological malignancies","volume":"18","author":"Rodriguez-Abreu","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.retram.2025.103563_bib0005","doi-asserted-by":"crossref","DOI":"10.1186\/s13287-021-02420-8","article-title":"Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.retram.2025.103563_bib0006","article-title":"Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.retram.2025.103563_bib0007","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/978-1-0716-0759-6_14","article-title":"Chimeric antigen receptor (CAR) T cell therapy for cancer. Challenges and opportunities: an overview","author":"Cort\u00e9s-Hern\u00e1ndez","year":"2021","journal-title":"Cancer Cell Signal"},{"key":"10.1016\/j.retram.2025.103563_bib0008","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/1924379","article-title":"CAR-T cell therapy in cancer: tribulations and road ahead","volume":"2020","author":"Zhang","year":"2020","journal-title":"J Immunol Res"},{"key":"10.1016\/j.retram.2025.103563_bib0009","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168996","article-title":"CAR T-cell therapy in hematological malignancies","volume":"22","author":"Haslauer","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.retram.2025.103563_bib0010","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/ajhp\/zxae046","article-title":"Recent and anticipated novel drug approvals for 2024","volume":"81","author":"Rim","year":"2024","journal-title":"Am J Health-Syst Pharm"},{"issue":"177","key":"10.1016\/j.retram.2025.103563_bib0011","doi-asserted-by":"crossref","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med"},{"issue":"16","key":"10.1016\/j.retram.2025.103563_bib0012","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.retram.2025.103563_bib0013","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9967","key":"10.1016\/j.retram.2025.103563_bib0014","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.retram.2025.103563_bib0015","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR\u2013T cells of defined CD4+: CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"issue":"16","key":"10.1016\/j.retram.2025.103563_bib0016","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor\u2013modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.retram.2025.103563_bib0017","first-page":"3312","article-title":"CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. Blood","volume":"127","author":"Park","year":"2016","journal-title":"J Am Soc Hematol"},{"key":"10.1016\/j.retram.2025.103563_bib0018","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12040842","article-title":"Chimeric antigen receptor cell therapy: overcoming obstacles to battle cancer","volume":"12","author":"Petty","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.retram.2025.103563_bib0019","doi-asserted-by":"crossref","DOI":"10.1177\/2155179018822781","article-title":"Approval of first CAR-ts: have we solved all hurdles for ATMPs?","volume":"11","author":"Seimetz","year":"2019","journal-title":"Cell Med"},{"issue":"19","key":"10.1016\/j.retram.2025.103563_bib0020","doi-asserted-by":"crossref","first-page":"6124","DOI":"10.3390\/jcm12196124","article-title":"Exploring CAR-T cell therapy side effects: mechanisms and management strategies","volume":"12","author":"Zhang","year":"2023","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.retram.2025.103563_bib0021","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.retram.2025.103563_bib0022","series-title":"Engineering strategies to mitigate toxicities associated with CAR-T cell therapy","author":"Wolter","year":"2024"},{"issue":"1","key":"10.1016\/j.retram.2025.103563_bib0023","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s40425-018-0460-5","article-title":"Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance","volume":"6","author":"Boyiadzis","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.retram.2025.103563_bib0024","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.ymthe.2019.03.011","article-title":"Adoptive transfer of NKG2D CAR mRNA-engineered natural killer cells in colorectal cancer patients","volume":"27","author":"Xiao","year":"2019","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.retram.2025.103563_bib0025","article-title":"Advances in immunotherapy with chimeric antigen receptor invariant natural killer T cells (CAR-iNKT cells); therapeutic implications in multiple myeloma","volume":"2","author":"Papoutselis","year":"2020","journal-title":"J Vaccinol"},{"issue":"1","key":"10.1016\/j.retram.2025.103563_bib0026","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.tmrv.2019.08.003","article-title":"Anti-CD19 CAR T-cell therapy for B-cell non-hodgkin lymphoma","volume":"34","author":"Abramson","year":"2020","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.retram.2025.103563_bib0027","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-020-1074-2","article-title":"Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis","volume":"26","author":"Heczey","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.retram.2025.103563_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1202950","article-title":"Beyond \u03b1\u03b2 T cells: NK, iNKT, and \u03b3\u03b4t cell biology in leukemic patients and potential for off-the-shelf adoptive cell therapies for AML","volume":"14","author":"Kent","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.retram.2025.103563_bib0029","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.925985","article-title":"CAR T-cell-based gene therapy for cancers: new perspectives, challenges, and clinical developments","volume":"13","author":"Jogalekar","year":"2022","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.retram.2025.103563_bib0030","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1111\/cas.14993","article-title":"CAR-NK cell in cancer immunotherapy; A promising frontier","volume":"112","author":"Marofi","year":"2021","journal-title":"Cancer Sci"},{"issue":"3","key":"10.1016\/j.retram.2025.103563_bib0031","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3390\/cancers15030663","article-title":"CAR-T: what is next?","volume":"15","author":"Chen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.retram.2025.103563_bib0032","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.omtm.2021.01.008","article-title":"Systematic improvements in lentiviral transduction of primary human natural killer cells undergoing ex vivo expansion","volume":"20","author":"Allan","year":"2021","journal-title":"Mol Ther-Methods Clin Dev"},{"issue":"6","key":"10.1016\/j.retram.2025.103563_bib0033","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.retram.2025.103563_bib0034","article-title":"CAR NK cell therapy in hematologic malignancies and solid tumors; obstacles and strategies to overcome the challenges","volume":"110","author":"Khorasani","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.retram.2025.103563_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: a promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.retram.2025.103563_bib0036","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40364-022-00364-6","article-title":"CAR-NK cells for cancer immunotherapy: from bench to bedside","volume":"10","author":"Zhang","year":"2022","journal-title":"Biomark Res"},{"issue":"1","key":"10.1016\/j.retram.2025.103563_bib0037","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41420-024-01815-9","article-title":"Breakthrough of solid tumor treatment: CAR-NK immunotherapy","volume":"10","author":"Wang","year":"2024","journal-title":"Cell Death Discov"},{"issue":"1","key":"10.1016\/j.retram.2025.103563_bib0038","article-title":"CAR-NK cells as promising immune therapeutics: platforms and current progress","volume":"17","author":"Salavatipour","year":"2024","journal-title":"Int J Cancer Manag"},{"issue":"1","key":"10.1016\/j.retram.2025.103563_bib0039","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41420-024-02077-1","article-title":"Emerging roles of CAR-NK cell therapies in tumor immunotherapy: current status and future directions","volume":"10","author":"Zhong","year":"2024","journal-title":"Cell Death Discov"},{"issue":"10","key":"10.1016\/j.retram.2025.103563_bib0040","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jtct.2022.06.025","article-title":"The next generation of cellular immunotherapy: chimeric antigen receptor-natural killer cells","volume":"28","author":"Moscarelli","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.retram.2025.103563_bib0041","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1007\/s12672-025-02489-0","article-title":"Evaluating the safety and feasibility of allogeneic NK cell infusion in high-risk lymphoma patients post-autologous stem cell transplantation","volume":"16","author":"Tavakoli","year":"2025","journal-title":"Discov Oncol"},{"issue":"3","key":"10.1016\/j.retram.2025.103563_bib0042","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.retram.2025.103563_bib0043","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41571-024-00866-2","article-title":"Promising early results with CAR NK cells","volume":"21","author":"Romero","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.retram.2025.103563_bib0044","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.847008","article-title":"Genetic engineering and enrichment of Human NK cells for CAR-enhanced immunotherapy of hematological malignancies","volume":"13","author":"Soldierer","year":"2022","journal-title":"Front Immunol"},{"issue":"25","key":"10.1016\/j.retram.2025.103563_bib0045","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2122379119","article-title":"Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia","volume":"119","author":"Dong","year":"2022","journal-title":"Proc Natl Acad Sci"},{"issue":"8","key":"10.1016\/j.retram.2025.103563_bib0046","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41408-021-00537-w","article-title":"NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma","volume":"11","author":"Leivas","year":"2021","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.retram.2025.103563_bib0047","first-page":"81","article-title":"Nobel Prize in physiology or medicine 2023: development of mRNA therapeutics that paved the path of formulation of COVID-19 vaccine","volume":"3","author":"Mandal","year":"2024","journal-title":"J Hematol Allied Sci"},{"key":"10.1016\/j.retram.2025.103563_bib0048","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.omtn.2022.07.003","article-title":"The legacy of mRNA engineering: a lineup of pioneers for the Nobel Prize","volume":"29","author":"Janowski","year":"2022","journal-title":"Mol Ther-Nucleic Acids"},{"key":"10.1016\/j.retram.2025.103563_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122810","article-title":"Delivering mRNA to a human NK cell line, NK-92 cells, by lipid nanoparticles","volume":"636","author":"Nakamura","year":"2023","journal-title":"Int J Pharm"},{"key":"10.1016\/j.retram.2025.103563_bib0050","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jconrel.2023.08.014","article-title":"Lipid nanoparticle-mediated messenger RNA delivery for ex vivo engineering of natural killer cells","volume":"361","author":"Douka","year":"2023","journal-title":"J Control Release"},{"issue":"17","key":"10.1016\/j.retram.2025.103563_bib0051","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241713364","article-title":"CAR-NK cells generated with mRNA-LNPs kill tumor target cells In vitro and In vivo","volume":"24","author":"Golubovskaya","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.retram.2025.103563_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113930","article-title":"Advances in mRNA non-viral delivery approaches","volume":"177","author":"Ibba","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"issue":"7","key":"10.1016\/j.retram.2025.103563_bib0053","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.ymthe.2017.03.001","article-title":"Current progress in non-viral RNAi-based delivery strategies to lymphocytes","volume":"25","author":"Mizrahy","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.retram.2025.103563_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101139","article-title":"Lipid nanoparticles outperform electroporation in mRNA-based CAR T cell engineering","volume":"31","author":"Kitte","year":"2023","journal-title":"Mol Ther-Methods Clin Dev"},{"issue":"1","key":"10.1016\/j.retram.2025.103563_bib0055","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41541-022-00528-3","article-title":"SARS-CoV-2 mRNA-vaccine candidate; COReNAPCIN\u00ae, induces robust humoral and cellular immunity in mice and non-human primates","volume":"7","author":"Alimohammadi","year":"2022","journal-title":"NPJ vaccines"},{"key":"10.1016\/j.retram.2025.103563_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112192","article-title":"Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: a double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up","volume":"134","author":"Salehi","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.retram.2025.103563_bib0057","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1186\/s12885-023-11610-x","article-title":"Phase I non-randomized clinical trial of allogeneic natural killer cells infusion in acute myeloid leukemia patients","volume":"23","author":"Ahmadvand","year":"2023","journal-title":"BMC cancer"},{"key":"10.1016\/j.retram.2025.103563_bib0058","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s12026-008-8072-7","article-title":"Endocytosis as a mechanism of regulating natural killer cell function: unique endocytic and trafficking pathway for CD94\/NKG2A","volume":"43","author":"Peruzzi","year":"2009","journal-title":"Immunol Res"},{"issue":"18","key":"10.1016\/j.retram.2025.103563_bib0059","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1111\/bph.14429","article-title":"Identification of novel macropinocytosis inhibitors using a rational screen of food and drug administration-approved drugs","volume":"175","author":"Lin","year":"2018","journal-title":"Br J Pharmacol"},{"issue":"4","key":"10.1016\/j.retram.2025.103563_bib0060","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1365-3083.2006.01803.x","article-title":"Resistance against natural killer cell cytotoxicity: analysis of mechanisms","volume":"64","author":"Hasenkamp","year":"2006","journal-title":"Scand J Immunol"},{"issue":"7","key":"10.1016\/j.retram.2025.103563_bib0061","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1084\/jem.20050499","article-title":"Understanding how combinations of HLA and KIR genes influence disease","volume":"201","author":"Rajagopalan","year":"2005","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.retram.2025.103563_bib0062","first-page":"839","article-title":"Interleukin-21 increases direct cytotoxicity and IFN-\u03b3 production of ex vivo expanded NK cells towards breast cancer cells","volume":"32","author":"Park","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.retram.2025.103563_bib0063","article-title":"Dose dependent antimicrobial cellular cytotoxicity\u2014Implications for ex vivo diagnostics","volume":"12","author":"Copaescu","year":"2021","journal-title":"Front Pharmacol"},{"issue":"1\u20132","key":"10.1016\/j.retram.2025.103563_bib0064","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0304-3835(99)00011-7","article-title":"A comparison of the NK cell cytotoxicity with effects of TNF-\u03b1 against K-562 cells, determined by LDH release assay","volume":"138","author":"Juri\u0161i\u0107","year":"1999","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1016\/j.retram.2025.103563_bib0065","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.coi.2004.11.001","article-title":"NK cells in innate immunity","volume":"17","author":"Hamerman","year":"2005","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"10.1016\/j.retram.2025.103563_bib0066","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/sj.cdd.4402170","article-title":"NK cells at the interface between innate and adaptive immunity","volume":"15","author":"Moretta","year":"2008","journal-title":"Cell Death Differ"},{"issue":"1","key":"10.1016\/j.retram.2025.103563_bib0067","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1021\/acs.nanolett.1c02503","article-title":"Orthogonal design of experiments for optimization of lipid nanoparticles for mRNA engineering of CAR T cells","volume":"22","author":"Billingsley","year":"2021","journal-title":"Nano Lett"},{"key":"10.1016\/j.retram.2025.103563_bib0068","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202301515","article-title":"Ionizable lipid nanoparticles with integrated Immune checkpoint inhibition for mRNA CAR","author":"Hamilton","year":"2023","journal-title":"T Cell Eng Adv Healthc Mater"},{"issue":"3","key":"10.1016\/j.retram.2025.103563_bib0069","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1021\/acs.nanolett.9b04246","article-title":"Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering","volume":"20","author":"Billingsley","year":"2020","journal-title":"Nano Lett"},{"key":"10.1016\/j.retram.2025.103563_bib0070","first-page":"1","article-title":"Safer non-viral DNA delivery using lipid nanoparticles loaded with endogenous anti-inflammatory lipids","author":"Patel","year":"2025","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.retram.2025.103563_bib0071","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114990","article-title":"Lipid nanoparticles (LNPs) for in vivo RNA delivery and their breakthrough technology for future applications","author":"Jeong","year":"2023","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.retram.2025.103563_bib0072","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.145854","article-title":"Antibody targeted delivery of lipid nanoparticles for RNA therapeutics to immune cells","author":"Kiaie","year":"2025","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.retram.2025.103563_bib0073","article-title":"Fabrication of active targeting lipid nanoparticles: challenges and perspectives","volume":"16","author":"Menon","year":"2022","journal-title":"Mater Today Adv"},{"issue":"6576","key":"10.1016\/j.retram.2025.103563_bib0074","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.retram.2025.103563_bib0075","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40580-021-00274-7","article-title":"Impact of the conjugation of antibodies to the surfaces of polymer nanoparticles on the immune cell targeting abilities","volume":"8","author":"Lee","year":"2021","journal-title":"Nano Converg"},{"key":"10.1016\/j.retram.2025.103563_bib0076","doi-asserted-by":"crossref","DOI":"10.3390\/biom10020263","article-title":"Recent advances in allogeneic CAR-T cells","volume":"10","author":"Kim","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.retram.2025.103563_bib0077","doi-asserted-by":"crossref","DOI":"10.1007\/s12094-020-02490-9","article-title":"Programmable and multi-targeted CARs: a new breakthrough in cancer CAR-T cell therapy","volume":"23","author":"Tahmasebi","year":"2021","journal-title":"Clin Transl Oncol"},{"issue":"1\u20132","key":"10.1016\/j.retram.2025.103563_bib0078","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2006.01.023","article-title":"Effective gene suppression using small interfering RNA in hard-to-transfect human T cells","volume":"312","author":"Yin","year":"2006","journal-title":"J Immunol Methods"},{"issue":"12","key":"10.1016\/j.retram.2025.103563_bib0079","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.3390\/cells10123390","article-title":"NK cells armed with chimeric antigen receptors (CAR): roadblocks to successful development","volume":"10","author":"Bashiri Dezfouli","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.retram.2025.103563_bib0080","doi-asserted-by":"crossref","DOI":"10.1021\/acsabm.4c00734","article-title":"Recent advances in biomaterials for mRNA delivery to immune cells","author":"Isaac","year":"2024","journal-title":"ACS Appl Bio Mater"},{"key":"10.1016\/j.retram.2025.103563_bib0081","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jconrel.2022.03.033","article-title":"Delivery of mRNA for regulating functions of immune cells","volume":"345","author":"Shi","year":"2022","journal-title":"J Control Release"},{"key":"10.1016\/j.retram.2025.103563_bib0082","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202301515","article-title":"Ionizable lipid nanoparticles with integrated Immune checkpoint inhibition for mRNA CAR","author":"Hamilton","year":"2023","journal-title":"T Cell Eng Adv Healthc Mater"},{"key":"10.1016\/j.retram.2025.103563_bib0083","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.3389\/fimmu.2018.02286","article-title":"Macropinocytosis: new insights into its underappreciated role in innate immune cell surveillance","volume":"9","author":"Canton","year":"2018","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.retram.2025.103563_bib0084","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/taap.1996.0068","article-title":"Tricyclic antidepressants inhibit human natural killer cells","volume":"137","author":"Xiao","year":"1996","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.retram.2025.103563_bib0085","first-page":"63","article-title":"NK cell-based tumor immunotherapy","volume":"31","author":"Zhang","year":"2024","journal-title":"Bioact mater"},{"key":"10.1016\/j.retram.2025.103563_bib0086","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3389\/fimmu.2017.01124","article-title":"The molecular mechanism of natural killer cells function and its importance in cancer immunotherapy","volume":"8","author":"Paul","year":"2017","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.retram.2025.103563_bib0087","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3390\/cancers12040952","article-title":"Natural killer cells: tumor surveillance and signaling","volume":"12","author":"Meza Guzman","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.retram.2025.103563_bib0088","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01178","article-title":"Natural killer T cells in cancer immunotherapy","volume":"8","author":"Nair","year":"2017","journal-title":"Front Immunol"},{"issue":"7978","key":"10.1016\/j.retram.2025.103563_bib0089","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s41586-023-06127-z","article-title":"Algorithm for optimized mRNA design improves stability and immunogenicity","volume":"621","author":"Zhang","year":"2023","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.retram.2025.103563_bib0090","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.cell.2018.12.021","article-title":"The landscape of circular RNA in cancer","volume":"176","author":"Vo","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.retram.2025.103563_bib0091","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jconrel.2022.05.043","article-title":"Circular RNA: an emerging frontier in RNA therapeutic targets, RNA therapeutics, and mRNA vaccines","volume":"348","author":"Liu","year":"2022","journal-title":"J Control Release"},{"key":"10.1016\/j.retram.2025.103563_bib0092","series-title":"Proceedings of the National Academy of Sciences","first-page":"14604","article-title":"Nonviral delivery of self-amplifying RNA vaccines","volume":"109","author":"Geall","year":"2012"},{"issue":"9","key":"10.1016\/j.retram.2025.103563_bib0093","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1021\/acsinfecdis.9b00084","article-title":"Mannosylation of LNP results in improved potency for self-amplifying RNA (SAM) vaccines","volume":"5","author":"Goswami","year":"2019","journal-title":"ACS Infect Dis"},{"issue":"2","key":"10.1016\/j.retram.2025.103563_bib0094","doi-asserted-by":"crossref","first-page":"822","DOI":"10.4314\/ahs.v20i2.36","article-title":"Effect of interleukins (IL-2, IL-15, IL-18) on receptors activation and cytotoxic activity of natural killer cells in breast cancer cell","volume":"20","author":"Widowati","year":"2020","journal-title":"Afr Health Sci"},{"key":"10.1016\/j.retram.2025.103563_bib0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar2336","article-title":"The proinflammatory cytokines IL-2, IL-15 and IL-21 modulate the repertoire of mature human natural killer cell receptors","volume":"9","author":"De Rham","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.retram.2025.103563_bib0096","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2025.07.021","article-title":"Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potency","author":"Biederst\u00e4dt","year":"2025","journal-title":"Cancer cell"},{"key":"10.1016\/j.retram.2025.103563_bib0097","first-page":"1","article-title":"CREM is a regulatory checkpoint of CAR and IL-15 signalling in NK cells","author":"Rafei","year":"2025","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.retram.2025.103563_bib0098","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004244","article-title":"Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity","volume":"10","author":"Bernard","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"Suppl 2","key":"10.1016\/j.retram.2025.103563_bib0099","first-page":"A123","article-title":"113 CISH gene-knockout anti-CD70-CAR NK cells demonstrate potent anti-tumor activity against solid tumor cell lines and provide partial resistance to tumor microenvironment inhibition","volume":"9","author":"Guo","year":"2021","journal-title":"J Immunother Cancer"}],"container-title":["Current Research in Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318625000728?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318625000728?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T17:52:37Z","timestamp":1775065957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452318625000728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":99,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2452318625000728"],"URL":"https:\/\/doi.org\/10.1016\/j.retram.2025.103563","relation":{},"ISSN":["2452-3186"],"issn-type":[{"value":"2452-3186","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipid nanoparticle mediated delivery of Anti-CD19 CAR mRNA to umbilical cord blood NK cells for targeting CD19\u207a primary B-ALL cells","name":"articletitle","label":"Article Title"},{"value":"Current Research in Translational Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.retram.2025.103563","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103563"}}